144 related articles for article (PubMed ID: 36716766)
1. The use of mTOR inhibitors for the treatment of kaposiform hemangioendothelioma. A systematic review.
Maza-Morales M; Valdés-Loperena S; Durán-McKinster LC; García-Romero MT
Pediatr Dermatol; 2023; 40(3):440-445. PubMed ID: 36716766
[TBL] [Abstract][Full Text] [Related]
2. Successful Everolimus Treatment of Kaposiform Hemangioendothelioma With Kasabach-Merritt Phenomenon: Clinical Efficacy and Adverse Effects of mTOR Inhibitor Therapy.
Matsumoto H; Ozeki M; Hori T; Kanda K; Kawamoto N; Nagano A; Azuma E; Miyazaki T; Fukao T
J Pediatr Hematol Oncol; 2016 Nov; 38(8):e322-e325. PubMed ID: 26907642
[TBL] [Abstract][Full Text] [Related]
3. Laryngomalacia and complicated, life-threatening mTOR-positive Kaposiform hemangioendothelioma cured by Supraglottoplasty and sirolimus.
Schroeder U; Lauten M; Stichtenoth G; Gebhard MP; Buchholz M; Kaiser MM
Klin Padiatr; 2014 Nov; 226(6-7):362-8. PubMed ID: 24810750
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical Analysis of mTOR Pathway-Related Proteins in Kaposiform Hemangioendothelioma.
Wang Z; Zheng C; Sun H; Yao W; Li K; Ma Y; Zheng S
Dermatology; 2020; 236(3):262-270. PubMed ID: 31896113
[TBL] [Abstract][Full Text] [Related]
5. Kaposiform hemangioendothelioma in children: a benign vascular tumor with multiple treatment options.
Schmid I; Klenk AK; Sparber-Sauer M; Koscielniak E; Maxwell R; Häberle B
World J Pediatr; 2018 Aug; 14(4):322-329. PubMed ID: 30054848
[TBL] [Abstract][Full Text] [Related]
6. [Refractory kaposiforme hemangioendothelioma in the pediatric population: case report and literature review.].
Gómez-Villegas CP; Pérez-Téllez C; Ochoa-Gaviria J; Builes N
Bol Med Hosp Infant Mex; 2021; 78(4):376-384. PubMed ID: 34351887
[TBL] [Abstract][Full Text] [Related]
7. Sirolimus therapy for kaposiform hemangioendothelioma with long-term follow-up.
Wang Z; Yao W; Sun H; Dong K; Ma Y; Chen L; Zheng S; Li K
J Dermatol; 2019 Nov; 46(11):956-961. PubMed ID: 31489702
[TBL] [Abstract][Full Text] [Related]
8. Sirolimus for the treatment of progressive kaposiform hemangioendothelioma: A multicenter retrospective study.
Ji Y; Chen S; Xiang B; Li K; Xu Z; Yao W; Lu G; Liu X; Xia C; Wang Q; Li Y; Wang C; Yang K; Yang G; Tang X; Xu T; Wu H
Int J Cancer; 2017 Aug; 141(4):848-855. PubMed ID: 28486787
[TBL] [Abstract][Full Text] [Related]
9. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals.
Croteau SE; Liang MG; Kozakewich HP; Alomari AI; Fishman SJ; Mulliken JB; Trenor CC
J Pediatr; 2013 Jan; 162(1):142-7. PubMed ID: 22871490
[TBL] [Abstract][Full Text] [Related]
10. Kaposiform Hemangioendothelioma with Kasabach-Merritt Phenomenon.
Pati S; Das MK; Rana A; Das E; Sarkar S; Sherpa N; Datta S
Indian J Pediatr; 2021 Nov; 88(11):1142-1144. PubMed ID: 34106442
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of Kaposiform hemangioendothelioma with everolimus.
Uno T; Ito S; Nakazawa A; Miyazaki O; Mori T; Terashima K
Pediatr Blood Cancer; 2015 Mar; 62(3):536-8. PubMed ID: 25306933
[TBL] [Abstract][Full Text] [Related]
12. Kaposiform hemangioendothelioma: current knowledge and future perspectives.
Ji Y; Chen S; Yang K; Xia C; Li L
Orphanet J Rare Dis; 2020 Feb; 15(1):39. PubMed ID: 32014025
[TBL] [Abstract][Full Text] [Related]
13. Kaposiform lymphangiomatosis and kaposiform hemangioendothelioma: similarities and differences.
Ji Y; Chen S; Peng S; Xia C; Li L
Orphanet J Rare Dis; 2019 Jul; 14(1):165. PubMed ID: 31277673
[TBL] [Abstract][Full Text] [Related]
14. Role of Sirolimus in Advanced Kaposiform Hemangioendothelioma.
Oza VS; Mamlouk MD; Hess CP; Mathes EF; Frieden IJ
Pediatr Dermatol; 2016; 33(2):e88-92. PubMed ID: 26864138
[TBL] [Abstract][Full Text] [Related]
15. Sirolimus, a promising treatment for refractory Kaposiform hemangioendothelioma.
Kai L; Wang Z; Yao W; Dong K; Xiao X
J Cancer Res Clin Oncol; 2014 Mar; 140(3):471-6. PubMed ID: 24464150
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus Treatment of an Infant With Intrathoracic Kaposiform Hemangioendothelioma Complicated by Life-threatening Pleural and Pericardial Effusions.
Duan L; Renzi S; Weidman D; Waespe N; Chami R; Manson D; Cada M; Carcao M
J Pediatr Hematol Oncol; 2020 Jan; 42(1):74-78. PubMed ID: 30044355
[TBL] [Abstract][Full Text] [Related]
17. Steroid-resistant kaposiform hemangioendothelioma: a retrospective study of 37 patients treated with vincristine and long-term follow-up.
Wang Z; Li K; Yao W; Dong K; Xiao X; Zheng S
Pediatr Blood Cancer; 2015 Apr; 62(4):577-80. PubMed ID: 25346262
[TBL] [Abstract][Full Text] [Related]
18. Rapamycin induces autophagy and apoptosis in Kaposiform hemangioendothelioma primary cells in vitro.
Wang Z; Han Q; Wang J; Yao W; Wang L; Li K
J Pediatr Surg; 2022 Jul; 57(7):1274-1280. PubMed ID: 35428493
[TBL] [Abstract][Full Text] [Related]
19. Development of Kasabach-Merritt phenomenon following vaccination: More than a coincidence?
Ji Y; Chen S; Yang K; Xia C; Peng S
J Dermatol; 2018 Oct; 45(10):1203-1206. PubMed ID: 30118141
[TBL] [Abstract][Full Text] [Related]
20. Retroperitoneal kaposiform hemangioendothelioma complicated by Kasabach-Merritt phenomenon and obstructive jaundice: A retrospective series of 3 patients treated with sirolimus.
Yao W; Li K; Wang Z; Dong K; Zheng S
Pediatr Dermatol; 2020 Jul; 37(4):677-680. PubMed ID: 32212177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
